<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Harold N Rosen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Clifford J Rosen, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth E Schmader, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 27, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Osteoporosis is characterized by low bone mass, microarchitectural disruption, and skeletal fragility, resulting in decreased bone strength and an increased risk of fracture. Decreased bone strength is related to many factors other than bone mineral density (BMD), including rates of bone formation and resorption (turnover), bone geometry (size and shape of bone), and microarchitecture  (
         <a class="graphic graphic_picture graphicRef73327" href="/z/d/graphic/73327.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p>
         The World Health Organization (WHO) has defined diagnostic thresholds for low bone mass and osteoporosis based upon BMD measurements compared with a young adult reference population (T-score). The majority of postmenopausal women with osteoporosis have bone loss related to estrogen deficiency and/or age.
        </p>
        <p>
         Early diagnosis and quantification of bone loss and fracture risk are important because of the availability of therapies that can slow or even reverse the progression of osteoporosis.
        </p>
        <p>
         The clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women will be reviewed here. The evaluation of osteoporosis in premenopausal women and men and the treatment of osteoporosis are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">
          "Evaluation and treatment of premenopausal osteoporosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2052.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of osteoporosis in men"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">
          "Treatment of osteoporosis in men"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Osteoporosis has no clinical manifestations until there is a fracture. This is an important fact because many patients without symptoms incorrectly assume that they must not have osteoporosis. On the other hand, many patients with achy hips or feet assume that their complaints are due to osteoporosis. This is unlikely true in the absence of fracture. In comparison, pain is common in osteomalacia in the absence of fractures or other bone deformities. (See
         <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">
          "Epidemiology and etiology of osteomalacia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vertebral fracture
         </strong>
         – Vertebral fracture is the most common clinical manifestation of osteoporosis. Most of these fractures (approximately two-thirds) are asymptomatic; they are diagnosed as an incidental finding on chest or abdominal radiograph  (
         <a class="graphic graphic_diagnosticimage graphicRef60593" href="/z/d/graphic/60593.html" rel="external">
          image 1
         </a>
         ). The clinical manifestations of symptomatic vertebral fracture, including height loss, are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7775.html" rel="external">
          "Osteoporotic thoracolumbar vertebral compression fractures: Clinical manifestations and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other fractures
         </strong>
         – Hip fractures are relatively common in osteoporosis, affecting up to 15 percent of women and 5 percent of men by 80 years of age [
         <a href="#rid1">
          1
         </a>
         ]. In addition, distal radius fractures (Colles fractures) may occur. Colles fractures are more common in women shortly after menopause, whereas the risk of hip fracture increases exponentially with age. (See
         <a class="medical medical_review" href="/z/d/html/226.html" rel="external">
          "Overview of common hip fractures in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/219.html" rel="external">
          "Distal radius fractures in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Osteoporosis is characterized by low bone mass, microarchitectural disruption, and increased skeletal fragility. A clinical diagnosis of osteoporosis may be made in the presence of  (
         <a class="graphic graphic_algorithm graphicRef142794" href="/z/d/graphic/142794.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid2">
          2-4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fragility fracture, particularly at the spine, hip, wrist, humerus, rib, and pelvis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         T-score ≤-2.5 standard deviations (SDs) at any site based upon bone mineral density (BMD) measurement by dual-energy x-ray absorptiometry (DXA) (see
         <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">
          "Screening for osteoporosis in postmenopausal women and men", section on 'Candidates for BMD testing'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         As another means for diagnosis of osteoporosis in postmenopausal women, we agree with the National Bone Health Alliance suggestion that a clinical diagnosis of osteoporosis may be made if there is a clear elevated risk for fracture [
         <a href="#rid3">
          3
         </a>
         ]. In the United States, for example, a clinical diagnosis of osteoporosis may be made when the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2035" target="_blank">
          FRAX
         </a>
         10-year probability of major osteoporotic fracture (hip, clinical spine, proximal humerus, or forearm) is ≥20 percent or the 10-year probability of hip fracture is ≥3 percent [
         <a href="#rid2">
          2,3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">
          "Osteoporotic fracture risk assessment", section on 'Fracture risk assessment tool'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Osteoporosis'
         </a>
         .)
        </p>
        <p>
         All postmenopausal women with osteoporosis should have an evaluation to exclude causes of low bone mass other than age and estrogen deficiency. (See
         <a class="local">
          'Evaluation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1722320505">
         <span class="h2">
          Fragility fracture
         </span>
         <span class="headingEndMark">
          —
         </span>
         A clinical diagnosis of osteoporosis may be made in the presence of a fragility fracture, particularly at the spine, hip, wrist, humerus, rib, and pelvis, without measurement of BMD. Fragility fractures are those occurring spontaneously or from minor trauma, such as a fall from a standing height or less. Fragility fractures result from mechanical forces that would not ordinarily result in fracture. Reduced bone density is a major risk factor for fragility fractures.
        </p>
        <p>
         The most common sites of fragility fracture are the spine (vertebral compression fractures), hip, and wrist. Fragility fractures also occur at the humerus, rib, and pelvis. Certain skeletal locations, including the skull, cervical spine, hands, feet, and ankles, are not associated with fragility fractures. Stress fractures are also not considered fragility fractures, as they are due to repetitive injury. (See
         <a class="medical medical_review" href="/z/d/html/255.html" rel="external">
          "Overview of stress fractures"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Bone mineral density
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the absence of a fragility fracture, BMD assessment by DXA is the standard test to diagnose osteoporosis, according to the classification of the World Health Organization (WHO) [
         <a href="#rid2">
          2,5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          T-score
         </span>
         <span class="headingEndMark">
          —
         </span>
         The WHO established diagnostic thresholds for BMD (by DXA) according to the SD difference between a patient's BMD and that of a young adult reference population (T-score)  (
         <a class="graphic graphic_table graphicRef74190" href="/z/d/graphic/74190.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ≤-2.5 SD
         </strong>
         – A BMD T-score that is 2.5 SD or more below the young adult mean BMD is defined as osteoporosis, provided that other causes of low BMD have been ruled out (such as osteomalacia)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          -1 to -2.5 SD
         </strong>
         – A T-score that is 1 to 2.5 SD below the young adult mean is termed low bone mass (osteopenia)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ≥-1 SD
         </strong>
         – Normal bone density is defined as a value within 1 SD of the mean value in the young adult reference population
        </p>
        <p>
        </p>
        <p>
         Individuals with T-scores of ≤-2.5 have the highest risk of fracture. However, collectively there are more fractures in patients with a T-score between -1 and -2.5 because there are so many more patients in this category [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2056.html" rel="external">
          "Overview of dual-energy x-ray absorptiometry"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Z-score
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Z-score is a comparison of the patient's BMD to an age-matched population. A Z-score of -2 or lower is considered below the expected range for age [
         <a href="#rid7">
          7
         </a>
         ]. Thus, the presence of Z-score values more than 2 SD below the mean should prompt careful scrutiny for coexisting problems (eg, glucocorticoid therapy or alcoholism) that can contribute to osteoporosis. (See
         <a class="local">
          'Additional evaluation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Applicability of WHO criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         The World Health Organization (WHO) thresholds were chosen based upon fracture risk in postmenopausal White women. Similar diagnostic threshold values for men are less well defined, although for any given BMD, the age-adjusted fracture risk is similar in men and women [
         <a href="#rid8">
          8
         </a>
         ]. We agree with the International Society for Clinical Densitometry (ISCD) recommendations for the application of the WHO classification in clinical practice [
         <a href="#rid7">
          7
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postmenopausal women and men ≥50 years
         </strong>
         – The ISCD advises that the WHO criteria be used in postmenopausal women and in men age 50 years and older.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Premenopausal women and men &lt;50 years
         </strong>
         – The ISCD advises that the WHO criteria
         <strong>
          not
         </strong>
         be used in premenopausal women or men under age 50 years, because the relationship between BMD and fracture risk is not the same in younger women and men.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Children
         </strong>
         – The WHO classification should
         <strong>
          not
         </strong>
         be used in children (male or female under age 20 years), and a diagnosis of osteoporosis cannot be made in a child based on densitometric criteria alone. Z-scores, not T-scores, should be used, since it is not appropriate to compare the BMD of someone who has not yet achieved peak bone mass with that of an adult who has. Osteoporosis can be diagnosed in children based on the presence of a vertebral compression fracture, or a Z-score &lt;-2 in combination with a significant fracture history (eg, two long bone fractures before age 10 years or three long bone fractures before 19 years) [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Method of BMD measurement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several different methods are available to measure bone mineral density (BMD). DXA is the best available clinical tool for the diagnosis of osteoporosis and monitoring changes in BMD over time. Detailed information about DXA is found elsewhere (see
         <a class="medical medical_review" href="/z/d/html/2056.html" rel="external">
          "Overview of dual-energy x-ray absorptiometry"
         </a>
         ). Other methods of measuring BMD for fracture risk assessment are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">
          "Osteoporotic fracture risk assessment", section on 'Methods of measurement of BMD'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Site of measurement
         </span>
         <span class="headingEndMark">
          —
         </span>
         In women who are candidates for BMD testing, we suggest DXA measurements of the spine and hip because fractures at these sites have the greatest impact on patients' health. Measurement of hip BMD also has the highest predictive value for hip fracture. In addition, if pharmacologic therapy is planned, measurement of spine BMD is useful as it shows less variability and can detect responses to therapy earlier than hip BMD. We make the diagnosis according to the lowest T-score measured.
        </p>
        <p>
         Interference from osteophytes and vascular calcifications on the spine measurement are common in aging women and interfere with the assessment of BMD at this site. In this setting, measurement of hip BMD alone or hip and one-third radial site is sufficient.
        </p>
        <p>
         In all studies, the risk for most fractures is inversely proportional to bone density [
         <a href="#rid10">
          10-18
         </a>
         ]. Some studies suggest that the risk for fracture at a particular site is best estimated by measuring bone density at that site [
         <a href="#rid19">
          19-22
         </a>
         ]. Other studies, however, have found that measurement of BMD at any site predicts fracture risk at all sites equally well [
         <a href="#rid23">
          23
         </a>
         ]. The preferred site for measurement of bone density and the number of sites to measure are debatable, and it may vary according to the clinical situation. The Fracture Risk Assessment Tool (FRAX) can improve the prediction of fractures above that achieved by BMD. (See
         <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">
          "Osteoporotic fracture risk assessment", section on 'Fracture risk assessment tool'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">
          "Screening for osteoporosis in postmenopausal women and men", section on 'Skeletal site to measure'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3329078">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Decreased bone mass can occur because peak bone mass is low, bone resorption is excessive, or bone formation during remodeling is decreased. All three processes are likely to contribute, in varying degrees, to osteoporosis in individual patients. Most postmenopausal women with osteoporosis, however, have either age- or estrogen deficiency-related bone loss due primarily to excessive bone resorption.
        </p>
        <p>
         Other causes of bone fractures and reduced bone mineral density (BMD) include osteomalacia, malignancy (eg, multiple myeloma), Paget disease, and hyperparathyroidism. Most of these diagnoses can be distinguished from estrogen deficiency-related osteoporosis by the clinical history, physical examination, and laboratory testing. (See
         <a class="local">
          'Evaluation'
         </a>
         below.)
        </p>
        <p>
         Physical abuse should always be considered a possibility in a patient with fractures, particularly when the fracture burden exceeds what one would expect based on BMD, or when location of fractures is atypical. (See
         <a class="medical medical_review" href="/z/d/html/3007.html" rel="external">
          "Elder abuse, self-neglect, and related phenomena", section on 'Warning signs'
         </a>
         .)
        </p>
        <p>
         Low BMD may also be seen in conjunction with renal osteodystrophy in patients with decreased kidney function [
         <a href="#rid24">
          24-26
         </a>
         ]. It is difficult to distinguish low bone density due to osteoporosis from low bone density due to any of the components of chronic kidney disease-metabolic bone disease. The distinction may be made biochemically in most cases, but may sometimes require bone biopsy. The diagnosis, evaluation, and management of osteoporosis in patients with chronic kidney disease and the diagnosis and management of renal osteodystrophy and secondary hyperparathyroidism are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/13914.html" rel="external">
          "Osteoporosis in patients with chronic kidney disease: Diagnosis and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7239.html" rel="external">
          "Evaluation of renal osteodystrophy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">
          "Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">
          "Management of secondary hyperparathyroidism in adult patients on dialysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of the evaluation is to exclude causes of low bone mass other than age and estrogen deficiency, such as osteomalacia, hyperthyroidism, and hyperparathyroidism, and to detect potentially remediable causes or other contributing factors to osteoporosis  (
         <a class="graphic graphic_table graphicRef54926" href="/z/d/graphic/54926.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid27">
          27-31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1291629037">
         <span class="h2">
          Initial evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial evaluation includes a history to assess for clinical risk factors for fracture and to evaluate for other conditions that contribute to bone loss, a physical examination, and basic laboratory tests.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History and physical examination
         </strong>
         – Most of the conditions causing osteoporosis can be excluded with a careful history and physical examination  (
         <a class="graphic graphic_table graphicRef54926" href="/z/d/graphic/54926.html" rel="external">
          table 2
         </a>
         ). Lifestyle factors that contribute to bone loss, including smoking, excessive alcohol, physical inactivity, and poor nutrition, should be addressed. Height and weight should be measured.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A history of a fragility fracture is an important risk factor for a subsequent fracture [
         <a href="#rid10">
          10,32,33
         </a>
         ]. In women who have a vertebral fracture, approximately 19 percent will have another fracture in the next year [
         <a href="#rid32">
          32
         </a>
         ]. A meta-analysis of 11 cohorts (15,259 men and 44,902 women) showed that a previous fracture was associated with an increased risk of any fracture compared with those without a prior fracture (relative risk [RR] 1.86, 95% CI 1.75-1.98) [
         <a href="#rid34">
          34
         </a>
         ]. Thus, individuals with a history of a fragility fracture are a high-risk group that requires evaluation and treatment. (See
         <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">
          "Osteoporotic fracture risk assessment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7775.html" rel="external">
          "Osteoporotic thoracolumbar vertebral compression fractures: Clinical manifestations and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory evaluation
         </strong>
         – We suggest that postmenopausal women with low BMD (T-score below -2.5) and/or fragility fracture have the following basic tests  (
         <a class="graphic graphic_table graphicRef62821" href="/z/d/graphic/62821.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid27">
          27,28,31,35
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Biochemistry profile (especially calcium, phosphorous, albumin, total protein, creatinine, liver enzymes including alkaline phosphatase, electrolytes)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         25-hydroxyvitamin D (25[OH]D)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complete blood count (CBC)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the diagnosis of osteoporosis is based upon the presence of a fragility fracture, we also obtain a BMD measurement (dual-energy x-ray absorptiometry [DXA]), performed on a nonurgent basis, for quantitative assessment of bone density and to monitor response to therapy
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Additional evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The need for additional laboratory evaluation depends upon the initial evaluation and Z-score  (
         <a class="graphic graphic_table graphicRef62821" href="/z/d/graphic/62821.html" rel="external">
          table 3
         </a>
         ). Women who have abnormalities on initial laboratory testing, suspicious findings on history and physical examination suggesting a secondary cause of osteoporosis, or Z-scores ≤-2 may require additional evaluation to detect these secondary causes  (
         <a class="graphic graphic_table graphicRef54926" href="/z/d/graphic/54926.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         24-hour urine for calcium and creatinine measurement is useful to assess for adequate calcium intake and absorption in women with gastrointestinal disorders, such as inflammatory bowel disease and celiac disease, or after gastrointestinal surgery, such as gastrectomy or bariatric surgery. Assessment of urinary calcium is also necessary in women with kidney stones, and it may be helpful in women with osteoporosis and no risk factors beyond age to identify idiopathic hypercalciuria [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2028.html" rel="external">
          "Metabolic bone disease in inflammatory bowel disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7375.html" rel="external">
          "Kidney stones in adults: Epidemiology and risk factors", section on 'High urine calcium'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A woman with unexplained anemia, vitamin D deficiency, and/or low urinary calcium excretion should be tested for celiac disease. (See
         <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">
          "Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Defining vitamin D sufficiency'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4771.html" rel="external">
          "Diagnosis of celiac disease in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4774.html" rel="external">
          "Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults", section on 'Metabolic bone disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cancer or multiple myeloma should be considered in patients who also have hypercalcemia, otherwise unexplained anemia, weight loss, or proteinuria. Measurement of serum and urine protein electrophoresis would be indicated in this case. (See
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum parathyroid hormone (PTH) should be measured in patients with hypercalcemia, hypercalciuria, a history of renal stones, or osteopenia. (See
         <a class="medical medical_review" href="/z/d/html/2029.html" rel="external">
          "Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinary cortisol excretion should be measured if Cushing syndrome is suspected and in patients with unexplained osteoporosis and vertebral fracture since patients with subclinical hypercortisolism (mild hypercortisolism without clinical manifestations of Cushing syndrome) are also at risk for low BMD and fractures. (See
         <a class="medical medical_review" href="/z/d/html/153.html" rel="external">
          "Evaluation and management of the adrenal incidentaloma", section on 'Subclinical Cushing syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/143.html" rel="external">
          "Epidemiology and clinical manifestations of Cushing syndrome", section on 'Bone loss'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18204108">
         <span class="h2">
          Bone turnover markers
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not routinely measure markers of bone turnover (BTMs) in postmenopausal women with osteoporosis. While the use of BTMs in clinical trials has been helpful in understanding the mechanism of action of therapeutic agents, their role in the care of individual patients is not well established. Potential roles of BTMs in clinical practice include prediction of fracture risk, monitoring response to therapy, and improving compliance with therapy. Biologic and laboratory variability in BTM values have confounded their widespread use in clinical practice. This topic is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2041.html" rel="external">
          "Use of biochemical markers of bone turnover in osteoporosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2880655858">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/105492.html" rel="external">
          "Society guideline links: Osteoporosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15482.html" rel="external">
          "Patient education: Osteoporosis (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15536.html" rel="external">
          "Patient education: Calcium and vitamin D for bone health (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/2160.html" rel="external">
          "Patient education: Osteoporosis prevention and treatment (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/2169.html" rel="external">
          "Patient education: Calcium and vitamin D for bone health (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Osteoporosis definition
         </strong>
         –
         <strong>
         </strong>
         Osteoporosis is characterized by low bone mass, microarchitectural disruption, and skeletal fragility, resulting in decreased bone strength and an increased risk of fracture. Decreased bone strength is related to many factors in addition to bone mineral density (BMD), including rates of bone formation and resorption (turnover), bone geometry (size and shape of bone), and microarchitecture  (
         <a class="graphic graphic_picture graphicRef73327" href="/z/d/graphic/73327.html" rel="external">
          picture 1
         </a>
         ). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         –
         <strong>
         </strong>
         Osteoporosis has no clinical manifestations until there is a fracture. Complications of fractures include pain, deformity, disability, and loss of height. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Fragility fracture
         </strong>
         –
         <strong>
         </strong>
         A clinical diagnosis of osteoporosis may be made in the presence of a fragility fracture, particularly at the spine, hip, wrist, humerus, rib, and pelvis, without measurement of BMD  (
         <a class="graphic graphic_algorithm graphicRef142794" href="/z/d/graphic/142794.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          DXA
         </strong>
         –
         <strong>
         </strong>
         In the absence of a fragility fracture, BMD assessment by dual-energy x-ray absorptiometry (DXA) is the standard test to diagnose osteoporosis, according to the classification of the World Health Organization (WHO)  (
         <a class="graphic graphic_table graphicRef74190" href="/z/d/graphic/74190.html" rel="external">
          table 1
         </a>
         ). A DXA T-score ≤-2.5 is consistent with osteoporosis, whereas a T-score between -1 and -2.5 is low bone mass (osteopenia). (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High fracture risk
         </strong>
         –
         <strong>
         </strong>
         For patients without a history of fragility fracture and without a DXA T-score ≤-2.5, a clinical diagnosis of osteoporosis may also be made if there is a clear elevated risk for fracture. In the United States, for example, a clinical diagnosis of osteoporosis may be made when the Fracture Risk Assessment Tool (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2035" target="_blank">
          FRAX
         </a>
         ) 10-year probability of major osteoporotic fracture is ≥20 percent or the 10-year probability of hip fracture is ≥3 percent. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         –
         <strong>
         </strong>
         All postmenopausal women with osteoporosis should have a history, physical examination, and basic laboratory evaluation. Initial laboratory studies should include a complete blood count (CBC), biochemistry profile, and 25-hydroxyvitamin D (25[OH]D). (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The need for additional laboratory evaluation depends upon the initial evaluation and Z-score  (
         <a class="graphic graphic_table graphicRef62821" href="/z/d/graphic/62821.html" rel="external">
          table 3
         </a>
         ). Women who have abnormalities on initial laboratory testing, suspicious findings on history and physical examination suggesting a secondary cause of osteoporosis, or Z-scores ≤-2 may require additional evaluation for these secondary causes  (
         <a class="graphic graphic_table graphicRef54926" href="/z/d/graphic/54926.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Additional evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         –
         <strong>
         </strong>
         The treatment of osteoporosis in postmenopausal women is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3420119056">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Marc K Drezner, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Svedbom A, Hernlund E, Ivergård M, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013; 8:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int 2014; 25:2359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 2014; 25:1439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morin SN, Lix LM, Leslie WD. The importance of previous fracture site on osteoporosis diagnosis and incident fractures in women. J Bone Miner Res 2014; 29:1675.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva 1994. http://whqlibdoc.who.int/trs/WHO_TRS_843.pdf (Accessed on March 09, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cranney A, Jamal SA, Tsang JF, et al. Low bone mineral density and fracture burden in postmenopausal women. CMAJ 2007; 177:575.
          </a>
         </li>
         <li class="breakAll">
          https://www.iscd.org/official-positions/2019-iscd-official-positions-adult/.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20:1185.
          </a>
         </li>
         <li class="breakAll">
          2019 ISCD Official Positions – Pediatric. https://www.iscd.org/official-positions/2019-iscd-official-positions-pediatric/ (Accessed on April 13, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Laet CE, Van Hout BA, Burger H, et al. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 1998; 13:1587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Genant HK, Engelke K, Fuerst T, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 1996; 11:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly TL, Slovik DM, Schoenfeld DA, Neer RM. Quantitative digital radiography versus dual photon absorptiometry of the lumbar spine. J Clin Endocrinol Metab 1988; 67:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada M, Ito M, Hayashi K, et al. Dual energy X-ray absorptiometry of the calcaneus: comparison with other techniques to assess bone density and value in predicting risk of spine fracture. AJR Am J Roentgenol 1994; 163:1435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seeley DG, Browner WS, Nevitt MC, et al. Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1991; 115:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hui SL, Slemenda CW, Johnston CC Jr. Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 1989; 111:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cummings SR, Black DM, Nevitt MC, et al. Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA 1990; 263:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melton LJ 3rd, Atkinson EJ, O'Fallon WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993; 8:1227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eastell R, Wahner HW, O'Fallon WM, et al. Unequal decrease in bone density of lumbar spine and ultradistal radius in Colles' and vertebral fracture syndromes. J Clin Invest 1989; 83:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cummings SR, Black D. Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med 1995; 98:24S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002; 288:1889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Black DM, Cummings SR, Genant HK, et al. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 1992; 7:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lobão R, Carvalho AB, Cuppari L, et al. High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis. Clin Nephrol 2004; 62:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller PD. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 2005; 3:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hofbauer LC, Hamann C, Ebeling PR. Approach to the patient with secondary osteoporosis. Eur J Endocrinol 2010; 162:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diab DL, Watts NB. Secondary osteoporosis: differential diagnosis and workup. Clin Obstet Gynecol 2013; 56:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hudec SM, Camacho PM. Secondary causes of osteoporosis. Endocr Pract 2013; 19:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller PD. Unrecognized and unappreciated secondary causes of osteoporosis. Endocrinol Metab Clin North Am 2012; 41:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2022; 33:2049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999; 14:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002; 87:4431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan LE, Ing SW. Idiopathic hypercalciuria and bone health. Curr Osteoporos Rep 2012; 10:286.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2035 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24113838" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Osteoporosis in the European Union: a compendium of country-specific reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25182228" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinician's Guide to Prevention and Treatment of Osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24577348" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24535832" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The importance of previous fracture site on osteoporosis diagnosis and incident fractures in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24535832" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The importance of previous fracture site on osteoporosis diagnosis and incident fractures in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17846439" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Low bone mineral density and fracture burden in postmenopausal women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17846439" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Low bone mineral density and fracture burden in postmenopausal women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15940371" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Predictive value of BMD for hip and other fractures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15940371" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Predictive value of BMD for hip and other fractures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2024857" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Pre-existing fractures and bone mass predict vertebral fracture incidence in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9783547" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Hip fracture prediction in elderly men and women: validation in the Rotterdam study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8725168" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Noninvasive assessment of bone mineral and structure: state of the art.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3417851" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Quantitative digital radiography versus dual photon absorptiometry of the lumbar spine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7992742" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Dual energy X-ray absorptiometry of the calcaneus: comparison with other techniques to assess bone density and value in predicting risk of spine fracture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1952469" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2764403" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Baseline measurement of bone mass predicts fracture in white women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8093403" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2404146" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8256660" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Long-term fracture prediction by bone mineral assessed at different skeletal sites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2910906" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Unequal decrease in bone density of lumbar spine and ultradistal radius in Colles' and vertebral fracture syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7709929" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12377088" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clinical use of bone densitometry: scientific review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1414481" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Axial and appendicular bone density predict fractures in older women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15630902" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16036095" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Treatment of osteoporosis in chronic kidney disease and end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16641930" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20231368" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Approach to the patient with secondary osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24100597" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Secondary osteoporosis: differential diagnosis and workup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23186949" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Secondary causes of osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22877432" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Unrecognized and unappreciated secondary causes of osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35478046" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The clinician's guide to prevention and treatment of osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11176842" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Risk of new vertebral fracture in the year following a fracture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10320531" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15268886" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A meta-analysis of previous fracture and subsequent fracture risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12364413" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23054957" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Idiopathic hypercalciuria and bone health.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
